Bowen Hanes & Co. Inc. Sells 28,655 Shares of Boston Scientific Corporation $BSX

Bowen Hanes & Co. Inc. reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 68.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,170 shares of the medical equipment provider’s stock after selling 28,655 shares during the quarter. Bowen Hanes & Co. Inc.’s holdings in Boston Scientific were worth $1,256,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at $26,000. Murphy & Mullick Capital Management Corp lifted its position in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares in the last quarter. United Community Bank lifted its position in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares in the last quarter. Colonial Trust Co SC lifted its position in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares in the last quarter. Finally, Bangor Savings Bank lifted its position in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BSX has been the topic of several analyst reports. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a research report on Thursday, May 28th. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a research report on Friday, February 6th. Leerink Partners dropped their target price on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a report on Thursday, May 28th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $55.00 price target (down from $75.00) on shares of Boston Scientific in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.79.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $47.79 on Thursday. The company’s 50 day moving average price is $58.92 and its two-hundred day moving average price is $77.28. Boston Scientific Corporation has a 12-month low of $47.17 and a 12-month high of $109.50. The firm has a market cap of $71.03 billion, a PE ratio of 19.99, a PEG ratio of 0.89 and a beta of 0.56. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the prior year, the business posted $0.75 EPS. The business’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.